MAP2K1 (MEK1) as a therapeutic target for arteriovenous malformations and associated disorders
The instant disclosure provides methods and compositions related to discovery of MAP2K (MEK1) as a therapeutic target for treatment or prevention of arteriovenous malformations (AVMs). Therapeutic and/or prophylactic uses and compositions of known MEK1 inhibitors, including small molecules and nucleic acid agents, are described.
1. A method for treating or preventing arteriovenous malformation (AVM) in a subject, the method comprising:
(a) identifying a subject having or at risk of AVM; and
(b) administering a MEK1 inhibitor to the subject,
thereby treating or preventing AVM in the subject,
wherein the MEK1 inhibitor is N-(3-{3-Cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-d]pyrimidin-1(2H)-yl}phenyl)acetamide (Trametinib), and
wherein administering is oral administration.
2. The method of claim 1 , wherein the AVM comprises a somatic MAP2K1 mutation that upregulates MEK1 levels and/or in one or more genes associated with a RAS/MAPK pathway.
3. The method of claim 2 , wherein the somatic MAP2K1 mutation comprising: Lys57Asn, Gln56Pro, Gln58_Glu62 del, Phe53Leu/Asp67Tyr, or combinations thereof.
4. The method of claim 3 , wherein the somatic MAP2K1 mutations comprise p.F53L and p.D67Y in cis.
5. The method of claim 1 , wherein the AVM is a solitary extracranial AVM selected from the group consisting of a facial AVM, a scalp AVM, an ear AVM, an upper lip AVM and an abdominal AVM.
6. The method of claim 1 wherein the AVM is a Stage I, Stage II or Stage III AVM.
7. The method of claim 1 , wherein the subject is a human.
8. The method of claim 1 , wherein the AVM location is recited in Table 2.
9. The method of claim 1 , further comprising administering an effective amount of one or more anti-angiogenic agents.
10. The method of claim 9 , wherein the anti-angiogenic agent comprises
sunitinib, angiostatin K1-3, arresten, DL-a-difluoromethyl-ornithine, fumagillin, genistein, staurosporine, (±)-thalidomide, tumstatin, axitinib, bortezomib, bosutinib gefitinib, pazopanib, semaxanib, sorafenib, vandetanib, vatalanib, canertinib, cilengitide, dovitinib, dasatinib, erlotinib, everolimus, imatinib, lapatinib, masutinib, marizomib, mubitinib, lestaurtinib, pazopanib, tandutinib, vismodegib or combinations thereof.
11. The method of claim 1 , further comprising administering an effective amount of one or more inhibitors of ERK1/2 comprising SCH772984, LY3214996, SC1, RasGAP, VX-11e, DEL-22379, Ulixertinib (BVD-523, VRT752271), GDC-0994, FR 180204, ERK5-IN-1, or combinations thereof.
12. The method of claim 2 , wherein the one or more genes associated with the RAS/MAPK pathway, comprise: HRAS, KRAS, NRAS, ARAF, BRAF, RAF1, MAP2K2, MAPK1, MAPK3, MAP3K3, or combinations thereof.
13. The method of claim 12 , wherein a mutation in HRAS is p.Thr58_Ala59delinsValLeuAspVal.